McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
|
|
- Opal Charles
- 6 years ago
- Views:
Transcription
1 McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
2 Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the FDA approved 39 new molecular entities, the highest level in a decade. We analyzed publicly available data in order to identify the drivers of the surge in new drug approvals and to understand whether the surge is sustainable. Much has been written about the pharmaceutical industry s challenge with R&D productivity during the past decade. Yet the number of innovative new drugs approved by the U.S. Food and Drug Administration (FDA) has accelerated significantly over the past few years an important measure of the output of the pharmaceutical R&D process. In 2012, the FDA approved 39 innovative new drugs the highest level in a decade. This promising surge has prompted many to ask whether it has been just a temporary uptick or perhaps even the beginning of a new phase of higher output and productivity. In this article, we show that both the industry and the FDA have played key roles in the higher levels of approvals. We also examine what will be necessary to sustain these levels. For the better part of the past decade, several related trends have driven a long-term decline in pharmaceutical R&D productivity: for example, there have been fewer new drug approvals, decreasing probability of success, and higher costs to discover and develop drugs. The decline has created the so-called patent cliff where biopharmaceutical companies have struggled to develop innovative new drugs to replace the blockbusters that have lost, or will soon lose, their exclusivity. In response, biopharmaceutical companies have undertaken fundamental initiatives to improve their productivity and return on investment. For example, they have focused their portfolios on disease areas with high unmet needs, culled low priority assets aggressively, controlled program costs by offshoring routine activities to lower-cost countries, and reduced their fixed costs by outsourcing to CROs. Other companies have abandoned R&D entirely and focused on inlicensing products. Meanwhile, investors have waited patiently to see signs of green shoots. Until recently, those shoots have been limited to a small number of innovative biopharmaceutical companies. 1
3 The recent surge in new drug approvals The number of new molecular entities (NMEs) approved by the FDA in a given year is one measure of the biopharmaceutical industry s innovation output. Exhibit 1 shows that, during the past 20 years, the annual number of innovative new drug approvals has been about 28. These approvals have seen several cycles of peaks and troughs, including a notable high of 53 in 1996 and a low of 17 in For much of the past decade, the number has lagged in the low to mid 20s. The pattern is consistent with the industry-wide decline in R&D productivity. Exhibit 1 New drug approval rate over time Number of NME/NBE approvals % % new drugs. Innovative therapies approved in the past few years promise major advances in the fields of oncology, cardiovascular disease, type 2 diabetes, and hepatitis C just to name a few. Other work has assessed trends and further segmented the number of approvals by the level of innovation apparent in the drug. The drivers of new drug approval rates Our goal in this article is to understand the drivers of the recent surge in new drug approvals and to assess whether those drivers can propel consistently high rates of approvals in the future. Our analysis of drug approvals uses a metric that can help with that assessment. We have identified three key components: the number of filings (labeled as n ), the FDA approval rate ( p ), and the regulatory review time ( t ). The new drug approval rate is proportional to n and p and inversely proportional to t. We systematically assessed each of those three components to understand its contribution to the recent increase in approval rates. Let s review each in turn: NME filings signaling the industry s innovative output, Prior 5 years, The number of approvals accelerated in 2011 and 2012, to about 24 percent above the longterm of 28. This boost prompted many to wonder whether past and present efforts to improve R&D productivity are beginning to pay off and if the downward trend in R&D productivity has been stemmed for good. In recent years, much has also been written about the quality and quantity of innovative After millions of dollars in investment, many years of time and effort, and numerous trials and subjects treated, a biopharmaceutical company may elect to file a new drug application (NDA) or biologics license application (BLA) with the FDA for a product that the company believes meets U.S. approval requirements. Filing an application with the FDA is a major milestone for the many professionals who have worked to discover and develop the product, as well as a time of great hope for patients and healthcare providers. Exhibit 2 shows that the annual number of innovative new drug filings has d about 35 for the past 20 years. That number 2
4 has fluctuated between a high of 50 in 1995 and a low of 23 in In 2011 and 2012, the number increased significantly to 39 and 41, respectively about 13 percent higher than the. Exhibit 3a The contribution of FDA approval rates to the increase in new drug approvals NME/NBE approval rate Percent of NME filings approved by FDA Exhibit 2 The contribution of filings to the increase in new drug approvals Number of NME/NBE filings : 79% % -13% , Prior 5 years, FDA s assessment of NME filings When the FDA receives an application, it assigns a cross-functional team of subject matter experts to review it and approve the product or to issue a complete response letter. In general, approval rates tend to be quite high since biopharmaceutical companies typically submit applications only when they believe they will meet the approval requirements. Another closely watched metric is the first action approval rate, which is the percentage of applications approved on the first action date. Exhibit 3b shows that the first action approval rate was about 45 percent during the past two decades. The rate reached a high of 79 percent in The rate of 77 percent was about 71 percent higher than the. Although first action approvals don t necessarily affect the overall approval rate, they provide faster access to innovative therapies. Exhibit 3b The contribution of FDA review times to the increase in new drug approvals NME/NBE first action approval rate Percent of approved NME/NBEs approved on first action date % % Exhibit 3a shows that the FDA approval rate for NMEs has d 79 percent over the past 20 years. From 2008 through 2012, the approval rate was 80 percent. Over the past 20 years, the five-year approval rate has fluctuated between a high of 88 percent between 1993 and 1997 and a low of 70 percent between 2003 and 2007., Prior 5 years,
5 The FDA has undertaken a number of steps to enhance the first action approval rate over time. Just-in-time inventory of NME filings In the era that began with 1993 s Prescription Drug User Fee Act (PDUFA), the FDA and the pharmaceutical industry agreed to performance goals for FDA application review timelines. Along with filing an application, the biopharmaceutical sponsor pays a user fee to help defray FDA review costs. In addition, the FDA now offers expedited pathways to shorten the approval time for innovative therapies that treat unmet medical needs. In particular, the priority review program shortens PDUFA performance goals from 10 months to six. These approaches have significantly reduced review times in the PDUFA era. with the increase in first action approval rates, the 75th percentile decreased in compared to the 10-year. Hence, while the median review time has stayed roughly the same, the tail of applications has recently decreased. Exhibit 4b shows the cumulative distribution of approval times. The distribution for is greater than or equal to the 10-year distribution, indicating, on, faster review times for drugs approved in compared to the 10-year. Exhibit 4b New drug approval times Cumulative probability Priority review Priority review + 3 month extension Standard review Standard review + 3 month extension Past 10 years Exhibit 4a shows that the top quartile and median times to approval have remained relatively constant. Not surprisingly, they are close to the PDUFA goals of about six to 10 months for priority and standard reviews, respectively. A further look at the distribution of review times demonstrates that, consistent Time to approval, days Exhibit 4a New drug approval times Number of days from NME/NBE filing to approval One way to understand this improvement is to view new drug filings under FDA review as workin-process inventory. Currently, about two-thirds of approvals are made within a year of first submission. In many ways, the shortened processing time and reduced work-in-process inventory at the FDA in recent years is akin to just-in-time inventory management with a high first-pass quality rate. There is little or no backlog of work-in-process inventory that could boost output in future periods. An integrated assessment Based on that breakdown of the components of NME approval rates, we conclude that the surge in s new drug approvals was driven by an increase in the number of NME filings by 4
6 biopharmaceutical companies and a decrease in review times, which was primarily due to higher first action approval rates. In other words, both the industry and the FDA played vital roles in the recent surge. The increase in the number of NME filings could represent a positive sign toward more innovative output by pharmaceutical companies. At the same time, the FDA s shorter review times could reflect a combination of factors, including the agency s increased ability to meet PDUFA review timeline performance goals and to communicate better with sponsors by, for example, setting clear expectations for approval requirements. Decreased review times may also reflect improvements in companies ability to prepare applications that meet FDA standards and avoid lengthy multiple cycles of review. Both of these factors are positive news; they also point to the fact the biopharmaceutical industry and the FDA are now able to collaborate more closely to bring innovative new therapies to patients. Temporary uptick or longer term trend? So are we seeing the beginning of a longer term trend? Or is the surge in approval rates just a temporary uptick? As noted, both the industry and the FDA contributed to the increase in new drug approvals in 2011 and But the number of approvals over the long term is dictated primarily by the number of industry filings; overall FDA approval rates are at or near their long-run and first action approval rates have increased significantly without much more room to increase further. Under the current FDA review paradigm, it is difficult to envision significant additional uplift in the number of approvals resulting from further improvements to approval rates and review times. approval rate of 79 percent, that number of filings would result in about 32 annual NME approvals. Even if the industry were to maintain its current rate of filings, there would be downward pressure on the number of approvals from current levels. Alternatively, maintaining the current level of innovative new drug approvals would require an NME filing rate above the current levels of about 40 per year. So if we look at current NME filings with PDUFA dates and also review the industry pipeline for assets that are currently finishing Phase 3 trials, we can see the potential to sustain annual new drug approval totals at slightly above the of about 28 annual approvals. While that is clearly not the same pace as the banner year of 2012, it is still a significant boost over the lean years in the early 2000s, from a quantity perspective at least. That improvement in pace provides new therapeutic options to patients with unmet medical needs. In addition, it may be sufficient to boost the pharmaceutical industry and reignite real growth. Some final observations: we also believe that the increased use of novel trial designs and regulatory approaches, such as the FDA s breakthrough therapy designation, has the potential to meaningfully accelerate clinical development programs. In turn, such initiatives may decrease overall cycle times for the industry, which could be another way of sustaining higher NME filing rates over the short term and medium term. Editor s note: All analyses in this article were conducted using publicly available data on FDA s website. Here is what the math looks like. Over the past two years, the industry has submitted 40 NME filings per year, on. Using the 5
7 McKinsey Center for Government October 2013 Layout by US Design Center Copyright McKinsey & Company
Speed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationFDA REVIEW PRINCIPLES EDMOND ROLAND, MD, FAHA AFSSAPS
FDA REVIEW PRINCIPLES EDMOND ROLAND, MD, FAHA AFSSAPS FDA REVIEW PRINCIPLES «A well-managed review process for an NDA or BLA begins with interactions between the applicant and the Agency s therapeutic
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationInsights into the Rare Disease Drug Approval Landscape: Trends and Current Development
Insights into the Rare Disease Drug Approval Landscape: Trends and Current Development Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough
More informationHow Have User Fees Affected the FDA?
HEALTH & MEDICINE How Have User Fees Affected the FDA? The 1992 FDA reform successfully reduced drug review times. Mary K. Olson Yale University D elay in the approval of new drugs has been a policy problem
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationState of the Clinical Trials Industry
State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and Development Market in Asia - Overview 3.1 Introduction 3.1.1
More informationComparative Analysis of FDA Review Times for Alzheimer s, HIV/AIDS, and Cancer Therapies
Comparative Analysis of FDA Review Times for Alzheimer s, HIV/AIDS, and Cancer Therapies Prepared by Avalere Health Lauren Barnes Allison Colbert Dan Mendelson June 2007 Prepared for ACT-AD (Accelerate
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations
More information2014 Was a Good Year for FDA & Pharma
Jan 2015 Vol. 14, No. 1 Pharma Marketing Network www.pharmamarketingnews.com 2014 Was a Good Year for FDA & Pharma Banging Year for Drug Approvals, Wimpy Year for Enforcement Actions Author: John Mack
More informationAssessing the Economics of Single-Source vs. Multi-Vendor Manufacturing
Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing Tufts Center for the Study of Drug Development, Tufts University School of Medicine Boston, MA October 2017 Joseph A. DiMasi, Ph.D.,
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationThe Future of Generic Pharmaceuticals
The Future of Generic Pharmaceuticals David R. Gaugh, R.Ph. Senior Vice President, Sciences and Regulatory Affairs Generic Pharmaceutical Association A Look Ahead Aging Demographics 1 YEARS OF AGE A Look
More informationTREND 2 Accelerating Evidence
TREND 2 Accelerating Evidence ACCELERATING EVIDENCE Regulators around the world are creating policies and collaborations to test novel science and technology faster, understand the real-world impact of
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationBREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D
BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical
More informationA New Approach to Outsourced Drug Development:
A New Approach to Outsourced Drug Development: How Sponsor-CRO Clinical Delivery Alliances Improve Performance Therapeutic Foresight. Trusted Results. Page 2 A New Approach to Outsourced Drug Development:
More informationISPE: Pharma Industry Outlook
ISPE: Pharma Industry Outlook ANDREW D. SKIBO Head of Global Biologics Operations & Global Engineering MedImmune/AstraZeneca Chairman, ISPE Board of Directors October 7, 2015 Linking Past ISPE Drivers
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationJohan Christenson MD; PhD Partner Farmasidagene 2014 Oslo
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo 1 HealthCap Focuses on Breakthrough Therapeutics Significant resource base Partners with profound sector experience Six MD PhD s Extensive network
More informationThe Timely Rise of the CDMO
OneSource Simplicity and speed. Delivered. The Timely Rise of the CDMO The healthcare sector can improve its margins by tens of billions of dollars and improve patient safety by making supply chain improvements.
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More information2018 FDA approvals: Robust momentum, landmark approvals & perpetuating impact of emerging ventures
Sathguru Insights Series 219 Healthcare & Lifesciences 218 FDA approvals: Robust momentum, landmark approvals & perpetuating impact of emerging ventures 218 FDA approvals: Robust momentum, landmark approvals
More informationAnnie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015
Annie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015 On behalf of Parent Project Muscular Dystrophy (PPMD), we are most grateful
More informationA Biotech Blockbuster in the $60 Billion Pet Industry. A Biotech Blockbuster in the $60 Billion Pet Industry
A Biotech Blockbuster in the $60 Billion Pet Industry Artana Therapeutics: Off the Radar and Undervalued Our next profile is a unique biopharma that is literally for the dogs, and that is a good thing
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationBringing an Excipient to Market
Bringing an Excipient to Market David Schaible JRS Pharma LP Excipientfest 2015 San Juan, PR Innovation and Excipients Do we need new excipients? Solubility challenges with new drugs Enable drug delivery
More informationPharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer
Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer Banc of America Healthcare Conference 2008 13 May 2008 Safe Harbor Except for historical information, all of the statements,
More informationDeployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA
PharmaSUG 2013 Paper MS04 Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA Abstract In pharmaceutical
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationList of Figures and Tables
1.01 p. 50 1.02 p. 50 1.03 p. 51 1.04 p. 51 1.05 p. 52 1.06 p. 52 1.07 p. 53 1.08 p. 53 1.09 p. 54 1.10 p. 54 1.11 p. 55 1.12 p. 55 1.13 p. 56 1.14 p. 56 1.15 p. 57 1.16 p. 57 1.17 p. 58 1.18 p. 58 1.19
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationTopics Covered. FDA s Role in Expediting the Development of Novel Medical Products. How a Regulatory Agency Comes into Existence 3/5/2018
FDA s Role in Expediting the Development of Novel Medical Products Peter Marks, M.D., Ph.D. Director Center for Biologics Evaluation and Research Topics Covered Brief history of FDA Expediting product
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationdevelopment trends for peptide therapeutics
2010 Report Summary development trends for peptide therapeutics december 2008 A comprehensive quantitative analysis of peptide therapeutics in clinical development PRINCIPAL INVESTIGATOR: Janice Reichert,
More informationPhRMA. Annual Press Conference
PhRMA Annual Press Conference February 1, 2017 Patrik Jonsson Chairman of Japan Based Executive Committee PhRMA Japanese Policy Changes Have Fostered Patients' Access to New Medicines Thanks to the transformation
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationCritics of the u.s. food and drug administration (fda) contend
Approval Times For New Drugs: Does The Source Of Funding For FDA Staff Matter? The amount of resources devoted to FDA review, not the source of funding, was likely the principal driver behind shrinking
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationEARLY PHASE DEVELOPMENT SOLUTIONS
EARLY PHASE DEVELOPMENT SOLUTIONS Real-world case studies demonstrating accelerated timelines, risk reduction and measurable cost savings are possible Early Phase Development Solutions is a unique drug
More informationPediatric Cancer Drug Development: Impact of US Regulations
Pediatric Cancer Drug Development: Impact of US Regulations Martha Donoghue, M.D. Acting Associate Director, Division of Oncology Products 2 Office of Hematology and Oncology Products Center for Drug Evaluation
More informationCollaborative Development Financing
Collaborative Development Financing 14 by Warren Nachlis and Wendy Brasunas The Growth of the Biotechnology Industry Pharmaceutical drug development is a risky and very expensive process. According to
More informationPAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market
PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your
More informationCAMD ANNUAL REGULATORY SCIENCE WORKSHOP OCTOBER 19, 2016 A CASE FOR INNOVATION, PROGRESS, AND OPTIMISM
CAMD ANNUAL REGULATORY SCIENCE WORKSHOP OCTOBER 19, 2016 A CASE FOR INNOVATION, PROGRESS, AND OPTIMISM ShaAvhrée Buckman-Garner, MD, PhD, FAAP Director, Office of Translational Sciences, CDER, FDA 1 OVERVIEW
More informationNew drug approvals in six major authorities : Focus on the availability of medicines and company size
Median approval time (days) New drug approvals in six major authorities 28 -: Focus on the availability of medicines and size Major improvements in the regulatory environment as well as changes in strategies
More informationA Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example
A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationPharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer
Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer R.W. Baird Growth Stock Conference 2008 14 May 2008 Safe Harbor Except for historical information, all of the statements,
More informationQuality Risk Management and Submission Strategies for Breakthrough Therapies
Quality Risk Management and Submission Strategies for Breakthrough Therapies IFPAC/Washington DC January 22, 2014 Sarah Pope Miksinski, Ph.D. Acting Director, Division of New Drug Quality Assessment 2
More informationPREVIEW. Benchmarking European Investigator Payments Industry Standard Research
PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation
More informationMethods for Expediting Innovative Novel Drugs to Market
1 Methods for Expediting Innovative Novel Drugs to Market Presented by: Ada Kung, ( 龔曉嘉博士 ) Ph.D. DABT, MBA akung@expedient-solutions.com www.expedient-solutions.com 2 FDA Guidance for Industry Expedited
More informationESTIMATING THE COST OF PHARMACEUTICALS MANAGING COST AND EXPECTATIONS
ESTIMATING THE COST OF PHARMACEUTICALS MANAGING COST AND EXPECTATIONS Thurman Gardner Bob Hunt ICEAA June 2018 Outline Presented at the 2018 ICEAA Professional Development & Training Workshop - www.iceaaonline.com
More informationYes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs
Yes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs 1 Kurt R. Karst Hyman, Phelps & McNamara, P.C. March 17, 2017 Agenda Drug Repurposing What is it? And why do it? Regulatory
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationNot Happy with Pharmacy Research? Let s Build a List of Research Priorities Together!
Not Happy with Pharmacy Research? Let s Build a List of Research Priorities Together! AMCP Research Prioritization Initiative (RPI) Disclaimer Organizations may not re use material presented at this AMCP
More informationAdopting Site Quality Management to Optimize Risk-Based Monitoring
WHITE PAPER Adopting Site Quality Management to Optimize Risk-Based Monitoring In today s pressure-packed environment, the quest for improved data quality at a lower cost is of paramount importance to
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationSpectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference
Spectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference June 3 rd, 2015 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements
More informationR&D Portfolio Planning In- and Out-licensing of Medicines
R&D Portfolio Planning In- and Out-licensing of Medicines Portfolio Planning Role of portfolio management Importance to Industry Tools, methods and models to make Go/No-Go decisions To help Prioritise
More informationEvolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors
HEALTHCARE Evolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors By Melissa Zebrowski Table of Contents Melissa Zebrowski Melissa Zebrowski has seven years of experience
More informationSelecting A Right Patient Recruitment Company: The Key To Success
Selecting A Right Patient Recruitment Company: The Key To Success A R T I C L E Toll Free Number: 1-888-987-2691 www.makrocare.com/mcsmo 1 With current global economic uncertainty, intense global competition,
More informationReducing the Time to Market with an eclinical System
Reducing the Time to Market with an eclinical System Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective owners. Copyright
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationThe Pharma/Payer Relationship Strategies for the Next Two Years
Health & Life Sciences The Pharma/Payer Relationship Strategies for the Next Two Years by Mark Mozeson Nipon Das, M.D. The power to determine what pharmaceutical products are bought and at what price has
More informationNew Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationStrategic Partnership
Strategic Partnership William J. Gole What is the issue? While strategic partnerships have grown in popularity in recent years, they often do not meet their intended objectives. Why is it important? Without
More informationIndustry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways
Industry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways Alan Poirier, Pfizer Inc. U.S. Regulatory Policy and Global Intelligence Worldwide Safety and Regulatory American
More informationKPI ENCYCLOPEDIA. A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS
KPI ENCYCLOPEDIA A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS www.opsdog.com info@opsdog.com 844.650.2888 Table of Contents Pharmaceuticals KPI Encyclopedia Pharmaceuticals Metric
More informationWebinar: Knowledge-based approaches to decreasing clinical attrition rates
Webinar: Knowledge-based approaches to decreasing clinical attrition rates Speakers: Dr. Richard K. Harrison Gavin Coney Teresa Fishburne May 2018 2 Clarivate Analytics is the global leader in providing
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationUtilizing Innovative Statistical Methods. Discussion Guide
Utilizing Innovative Statistical Methods and Trial Designs in Rare Disease Settings Discussion Guide Background Rare diseases are a complex and diverse set of conditions which, when taken together, affect
More informationPediatric Exclusivity and Drug Development Requirements in the Overall Pediatric Population. Prepared by Beckloff Associates, Inc.
and Drug Development Requirements in the Overall Pediatric Population 1 INTRODUCTION AND OVERVIEW Prepared by Beckloff Associates, Inc. Although children suffer from many of the same diseases as adults
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationSmall Molecule API Volumes Trends from the last 15 years of NCEs
Small Molecule API Volumes Trends from the last 15 years of NCEs A Cambrex webinar overview Yvonne Famorca Associate Research Scientist Where do CMOs like Cambrex need to invest? Innovation in the small
More informationBioProcess Technology Group. Helping Clients De-Risk Biopharmaceutical Development Since 1994
Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting clients
More informationStrategic Plan. Uniting to care & cure
2017-2020 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2020 Objectives & Strategies Page 6 Mission
More informationChallenges and Solutions in Clinical Supply Management. Pamela Osborne Sr. Clinical Supply Chain Mgr
01 Challenges and Solutions in Clinical Supply Management Pamela Osborne Sr. Clinical Supply Chain Mgr 02 Session Objectives Key Takeaways: Aspects to consider when supply planning Influence of early decisions
More informationThe Importance of Feasibility Studies for Oncology Clinical Trials
The Importance of Feasibility Studies for Oncology Clinical Trials www.ppdi.com Executive Summary The segmenting of the oncology patient population has increased the challenges in designing clinical trials.
More informationThe Future of Pharmaceutical Quality
The Future of Pharmaceutical Quality First SQA/BIRS Center Meeting Purdue University Polytechnic Institute Louis W. Yu, Ph.D. Chief Quality Officer Unique Challenges of the Pharmaceutical Industry a. The
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationClinical Supply Packaging for Biological Products
Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply
More informationClinical Trial Methods Course 2017 Trials in Rare Diseases. Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017
Clinical Trial Methods Course 2017 Trials in Rare Diseases Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017 Overview Challenges in studying rare diseases Strategies for trial
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationTHE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE
THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE Ali Mohamadi, M.D. Senior Director, Global Regulatory Patient Engagement and Policy BioMarin Pharmaceutical 30-July-2016 Goals of Today s Presentation
More informationClinical Trials A Closer Look
The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics
More information